Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132021) titled 'An open-label, multicenter, exploratory Phase II clinical study of the efficacy and safety of TR115 in patients with advanced solid tumors with ARID1A mutations' on Sept. 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Fudan University Shanghai Cancer Center
Condition:
Advanced Solid Tumors
Intervention:
Un-grouped, Queue 1: Ovarian, fallopian tube or peritoneal clear cell carcinoma
:Oral TR115 Tablets
Queue 2: Endometrial cancer:Oral TR115 Tablets
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-30
Target Sample Size: Un-grouped, Queue 1: ...